Whether Hepatitis B “minor triple positive” patients need to take medication should be combined with liver function, abdominal ultrasound, Hepatitis B virus (HBV) DNA, abdominal ultrasound and other indicators to make a comprehensive judgment. Hepatitis B “small triple positive” refers to three positive items of hepatitis B surface antigen, e antibody and core antibody. 1. Hepatitis B “small triple positive” patients, if the liver function is normal, but the abdominal ultrasound shows chronic liver disease, it is considered that it is e antigen negative chronic hepatitis B. At this time, there may be HBVDNA ≥ 2×106IU/ml, and the liver is likely to develop into cirrhosis in the process of repeated or sustained inflammation and repair, and then further develop into liver cancer, and at this time, it may develop into liver cancer. The liver may develop into liver cancer, which requires active antiviral treatment. 2. For patients with normal liver function and abdominal ultrasound and negative HBVDNA or <2×106IU/ml, generally no treatment is needed, but there is still a certain risk of mother-to-child transmission, so it is necessary to consult with a specialized doctor to decide whether to take antiviral drugs after weighing the pros and cons. Note: Hepatitis B "small triple positive" patients should undergo regular checkups and develop coping strategies according to changes in the test indicators. Newborns of HBsAg-positive mothers should be vaccinated against Hepatitis B at the appropriate time after birth.